Click Therapeutics vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
$50M Series D from Boehringer Ingelheim in Apr 2026. Develops prescription digital therapeutics for depression, schizophrenia, and other conditions.
About
Click Therapeutics develops FDA-regulated prescription digital therapeutics (PDT) for conditions including depression, schizophrenia, migraine, and smoking cessation. The company partners with pharma — including Boehringer Ingelheim, Otsuka, and Sanofi — to co-develop and commercialize PDTs alongside traditional pharmacologic treatments.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.